Anika Therapeutics (ANIK) Capital Expenditures (QoQ) (2010 - 2026)
Anika Therapeutics (ANIK) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn |
| 3 | Zoetis | 32.69 Bn | 30.75 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.61 Bn | 23.55 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.21 Bn | 21.06 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 205.06 Mn | 138.27 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.19% |
| Dec 31, 2025 | 259.58% |
| Sep 30, 2025 | -212.30% |
| Jun 30, 2025 | 654.78% |
| Mar 31, 2025 | -3.65% |
| Dec 31, 2024 | 110.23% |
| Sep 30, 2024 | -210.98% |
| Jun 30, 2024 | 637.78% |
| Mar 31, 2024 | -66.20% |
| Dec 31, 2023 | -47.83% |
| Sep 30, 2023 | 365.39% |
| Jun 30, 2023 | -195.68% |
| Mar 31, 2023 | -81.17% |
| Dec 31, 2022 | 1,389.86% |
| Sep 30, 2022 | 11.46% |
| Jun 30, 2022 | -148.72% |
| Mar 31, 2022 | 17.66% |
| Dec 31, 2021 | -12.23% |
| Sep 30, 2021 | -40.61% |
| Jun 30, 2021 | 279.30% |